Join
Live feed
·
PRReleasevia Quantisnow
First Tracks Biotherapeutics Inc. logo

First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease

ByQuantisnow·Wall Street's wire, on your screen.
TRAX· First Tracks Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TRAX (First Tracks Biotherapeutics Inc.) and more on Quantisnow.